Unit of Diabetes, Universidade Estadual do Rio de Janeiro, Avenida 28 de Setembro, 77, 3 andar CEP 20.551-030 Rio de Janeiro, Brazil.
Bauru's Diabetics Association, Bauru, São Paulo, Brazil.
Diabetol Metab Syndr. 2014 May 31;6:67. doi: 10.1186/1758-5996-6-67. eCollection 2014.
To evaluate the determinants of intensive insulin regimens (ITs) in patients with type 1 diabetes (T1D).
This multicenter study was conducted between December 2008 and December 2010 in 28 public clinics in 20 Brazilian cities. Data were obtained from 3,591 patients (56.0% female, 57.1% Caucasian). Insulin regimens were classified as follows: group 1, conventional therapy (CT) (intermediate human insulin, one to two injections daily); group 2 (three or more insulin injections of intermediate plus regular human insulin); group 3 (three or more insulin injections of intermediate human insulin plus short-acting insulin analogues); group 4, basal-bolus (one or two insulin injections of long-acting plus short-acting insulin analogues or regular insulin); and group 5, basal-bolus with continuous subcutaneous insulin infusion (CSII). Groups 2 to 5 were considered IT groups.
We obtained complete data from 2,961 patients. Combined intermediate plus regular human insulin was the most used therapeutic regimen. CSII was used by 37 (1.2%) patients and IT by 2,669 (90.2%) patients. More patients on IT performed self-monitoring of blood glucose and were treated at the tertiary care level compared to CT patients (p < 0.001). The majority of patients from all groups had HbA1c levels above the target. Overweight or obesity was not associated with insulin regimen. Logistic regression analysis showed that economic status, age, ethnicity, and level of care were associated with IT (p < 0.001).
Given the prevalence of intensive treatment for T1D in Brazil, more effective therapeutic strategies are needed for long term-health benefits.
评估 1 型糖尿病(T1D)患者强化胰岛素治疗方案(IT)的决定因素。
这项多中心研究于 2008 年 12 月至 2010 年 12 月在巴西 20 个城市的 28 个公共诊所进行。共纳入 3591 例患者(56.0%女性,57.1%白种人),获取其数据。胰岛素治疗方案分为以下几类:1 组为常规治疗(CT)(中效人胰岛素,每日 1-2 次注射);2 组(3 次或更多次中效与人胰岛素联用普通胰岛素注射);3 组(3 次或更多次中效人胰岛素联合短效胰岛素类似物注射);4 组,基础-餐时(1 或 2 次长效与短效胰岛素类似物或普通胰岛素注射);5 组,基础-餐时胰岛素输注(CSII)。2 组至 5 组被认为是 IT 组。
我们获得了 2961 例患者的完整数据。联合中效与人胰岛素是最常用的治疗方案。37 例(1.2%)患者接受 CSII 治疗,2669 例(90.2%)患者接受 IT 治疗。与 CT 患者相比,接受 IT 治疗的患者更常进行自我血糖监测,并在三级保健机构接受治疗(p<0.001)。所有组别的大多数患者的 HbA1c 水平均高于目标值。超重或肥胖与胰岛素方案无关。Logistic 回归分析显示,经济状况、年龄、种族和医疗水平与 IT 相关(p<0.001)。
鉴于巴西 T1D 强化治疗的流行,需要更有效的治疗策略以长期获益。